Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Dr. Kirkman received her BA in Biology from Swarthmore College. She received her medical degree from Albert Einstein College of Medicine with distinction in research where she spent time as a Howard Hughes Medical Student Research Fellow. Following that, she completed her internal medicine residency at Yale New Haven Hospital and fellowship training in Infectious Diseases at New York Presbyterian- Cornell. Post fellowship, she spent time as a post doc in the laboratory of Dr. Kirk Deitsch studying the human malaria parasite Plasmodium falciparum. Her current research continues to focus on malaria including an NIH funded study of the generation of genetic diversity in this important human pathogen.

Highlights

  1. 1
    mBio · 2020
    KWKirk W DeitschLKLaura Kirkman
    PMID: 32184256PMCID: PMC7078485DOISenior author17 citations
  2. 2
    The Journal of experimental medicine · 2021
    LKLaura Kirkman
    PMID: 34807244PMCID: PMC8611732DOISenior author4 citations
  3. 3
    Nucleic acids research · 2025
    AVAkshay VishwanathaKWKirk W DeitschLKLaura Kirkman
    PMID: 41277688PMCID: PMC12641262DOISenior author2 citations

Publications

49 publications

Funding

11 grantsView NIH portfolio on RePORTER ↗

Active

3 grants
  • PI
    Chromosomal Organization and DNA Repair Mechanisms in Plasmodium falciparum: Implications for Antigenic Variation and Maintenance of Genome Integrity
    National Institute of Allergy and Infectious Diseases · 2026–2031
    R01AI197390-01A1
  • Co-I
    Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials
    National Institute of Allergy and Infectious Diseases · 2019–2029· 2 renewals
    R01AI143714-08
  • Co-I
    Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance
    National Institute of Allergy and Infectious Diseases · 2023–2028· 2 renewals
    R01AI177635-01
Completed grants (8)
  • PI
    Role of Translesional Polymerases in Genome Diversification of the Malaria Parasite
    National Institute of Allergy and Infectious Diseases · 2019–2025· 2 renewals
    R01AI146153-05S1
  • Co-I
    Targeting the Plasmodium proteasome for prophylaxis and treatment of drug-resistant malaria in US Military personnel
    U.S. Department of Defense · 2022–2024 · via The Board of Trustees of the Leland Stanford Junior University
    W81XWH-22-1-0521
  • PI
    Investigating the proteasome of the malaria parasite Plasmodium falciparum
    The Brockman Foundation · 2019–2024
    BF 190027-03
  • Co-I
    Compounds that force Plasmodium falciparum to produce its own inhibitors
    National Institute of Allergy and Infectious Diseases · 2020–2023
    R21AI153485-02
  • Co-I
    Probing Mechanisms of P. Falciparum Artemisinin Resistance Using Single Cell Transcriptomics
    U.S. Department of Defense · 2018–2020
    No publications yet
    W81XWH1810222
  • KP
    Novel Inhibitors of Malaria Proteasome
    National Institute of Allergy and Infectious Diseases · 2017–2020
    R21AI123794-02
  • KP
    DNA Repair and Recombination Within the Var Gene Family of P. falciparum
    National Institute of Allergy and Infectious Diseases · 2012–2018
    R01AI099327-04
  • PI
    Genetic diversity in virulence genes of Plasmodium falciparum
    NIAID · 2008–2012 · via NIH RePORTER
    K08AI076635-05

News mentions

1 mentionView all WCM news ↗
  • Structural Study Points the Way to Better Malaria Drugs
    January 18, 2024

    Structural insights into a potent antimalarial drug candidate’s interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.

Mentoring

2 menteesAll publications with mentees →